Replies to post #24 on Allogene Therapeutics (ALLO)

[jondoeuk]

Was that the case study (50-year-old female)?

I know the CAR-T is already in registrational trials both in China and the US. If all goes to plan, they expected to submit an NDA to the NMPA in 2024 and a BLA to the FDA in 2025. A next-gen version is in the clinic as well https://aacrjournals.org/clincancerres/article/26/20/5494/82735/Coexpression-of-IL7-and-CCL21-Increases-Efficacy

Also https://www.biospace.com/article/moderna-carsgen-join-forces-combining-mrna-cancer-vaccine-with-car-t/

However, it's getting pretty crowded